how_does_COVID_19_affect_hemoglobin_matt_gray_vitamin_c_riboflavin_b2_patent

how_does_COVID_19_affect_hemoglobin_matt_gray_vitamin_c_riboflavin_b2_patent

Figure 1 in patent pending composition of medicines and therapeutic treatments for COVID-19, SARS-CoV, SARS-CoV-2, and MERS-CoV viruses against non-enzymatic glycation at the 1-beta chain of hemoglobin.